CSBR (Champions Oncology) Total Assets: $28.45 Mil (As of Jan. 2026)


CSBR Champions Oncology Inc CSBR
64 GF Score
Price $6.17
GF Value $6.62
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Champions Oncology Total Assets?

Champions Oncology CSBR -3.02% 64 Total Assets is $28.45 Mil as of Jan. 2026. GuruFocus rates CSBR with a GF Score™ of 64/100 and a GF Value™ of $6.62 (Fairly Valued). The stock has 2 warning signs investors should review.

Champions Oncology's Total Assets for the quarter that ended in Jan. 2026 was $28.45 Mil.

During the past 12 months, Champions Oncology's average Total Assets Growth Rate was -22.30% per year. During the past 3 years, the average Total Assets Growth Rate was -5.10% per year. During the past 5 years, the average Total Assets Growth Rate was 8.90% per year. During the past 10 years, the average Total Assets Growth Rate was 28.00% per year.

During the past 13 years, Champions Oncology's highest 3-Year average Total Assets Growth Rate was 96.20%. The lowest was -29.30%. And the median was 15.40%.

Total Assets is connected with ROA %. Champions Oncology's annualized ROA % for the quarter that ended in Jan. 2026 was -3.81%. Total Assets is also linked to Revenue through Asset Turnover. Champions Oncology's Asset Turnover for the quarter that ended in Jan. 2026 was 0.57.

Champions Oncology  (NAS:CSBR) Total Assets Explanation

Total Assets is connected with ROA %.

Champions Oncology's annualized ROA % for the quarter that ended in Jan. 2026 is

ROA %=Net Income (Q: Jan. 2026 )/( (Total Assets (Q: Oct. 2025 )+Total Assets (Q: Jan. 2026 ))/ count )
=-1.116/( (30.162+28.447)/ 2 )
=-1.116/29.3045
=-3.81 %

Note: The Net Income data used here is four times the quarterly (Jan. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Champions Oncology's Asset Turnover for the quarter that ended in Jan. 2026 is

Asset Turnover
=Revenue (Q: Jan. 2026 )/( (Total Assets (Q: Oct. 2025 )+Total Assets (Q: Jan. 2026 ))/ count )
=16.559/( (30.162+28.447)/ 2 )
=16.559/29.3045
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Champions Oncology Total Assets Related Terms

Champions Oncology Total Assets Historical Data

* Premium members only.

The historical data trend for Champions Oncology's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Champions Oncology Total Assets Chart

Champions Oncology Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.59 35.38 34.31 26.13 32.34

Champions Oncology Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.63 32.34 30.55 30.16 28.45
CSBR
64GF Score
Champions Oncology Inc CSBR
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Champions Oncology Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Champions Oncology's Total Assets for the fiscal year that ended in Apr. 2025 is calculated as

Total Assets=Total Equity (A: Apr. 2025 )+Total Liabilities (A: Apr. 2025 )
=3.772+28.572
=32.34

Champions Oncology's Total Assets for the quarter that ended in Jan. 2026 is calculated as

Total Assets=Total Equity (Q: Jan. 2026 )+Total Liabilities (Q: Jan. 2026 )
=4.378+24.069
=28.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $28.45 Mil mean?
Champions Oncology (CSBR) has a Total Assets of $28.45 Mil as of Jan. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Champions Oncology and its competitors.
Is Champions Oncology's Total Assets too high?
Champions Oncology's current Total Assets is $28.45 Mil. Overall, Champions Oncology has a GF Score™ of 64/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Champions Oncology's Total Assets compare to SEER and RLYB?
Champions Oncology's Total Assets of $28.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Champions Oncology and its competitors. Champions Oncology's current Total Assets is $28.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Champions Oncology stock overvalued right now?
Based on GuruFocus' analysis, Champions Oncology (CSBR) is currently considered Fairly Valued. The stock's GF Value™ is $6.62, compared to a current price of $6.17 — trading 6.8% below its estimated fair value. The current Total Assets is $28.45 Mil. Champions Oncology's overall GF Score™ is 64/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Champions Oncology (CSBR), the current Total Assets is $28.45 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Champions Oncology (CSBR) Overvalued in 2026?

Based on GuruFocus' analysis, Champions Oncology stock appears to be undervalued. The current stock price of $6.17 is trading 6.8% below its estimated GF Value™ of $6.62. GuruFocus considers Champions Oncology to be Fairly Valued.

Key valuation signals for CSBR:

  • Total Assets: $28.45 Mil
  • GF Value™: $6.62 vs. price of $6.17 (6.8% below fair value)
  • GF Score™: 64/100 with 2 warning signs

No single metric tells the full story. See the CSBR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Champions Oncology Business Description

Address One University Plaza, Suite 307, Hackensack, NJ, USA, 07601
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.
64GF Score

Get the complete analysis for CSBR

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.17
Price
$6.62
GF Value